Osaic Holdings
NTLA icon

Osaic Holdings’s Intellia Therapeutics NTLA Stock Holding History

Osaic Holdings’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.75K Buy
+35
New +$446 ﹤0.01% 7085
2022
Q1 		– Sell
-1
Closed -$1K – 7415
2021
Q4 		$1K Buy
+1
New +$125 ﹤0.01% 7219

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings's NTLA Position: Q1 2026 in Review

Osaic Holdings reduced its Intellia Therapeutics (NTLA) stake by 14% in Q1 2026, selling an estimated $40K and leaving 19,985 shares worth $256K. The position accounts for ﹤0.01% of the portfolio, ranked #3942.

Osaic Holdings first reported a position in NTLA in Q1 2020 and has held it in 25 quarters since. The position peaked at $1.72M in Q2 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Osaic Holdings held 19,985 shares of Intellia Therapeutics worth $256K as of Q1 2026.
  • Osaic Holdings sold 3,137 Intellia Therapeutics shares in Q1 2026, an estimated $40K.
  • Intellia Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q1 2026, its #3942 holding.
  • Osaic Holdings first reported a position in Intellia Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Osaic Holdings's Intellia Therapeutics position peaked at $1.72M in Q2 2021.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.